IRIS
BILO', Maria Beatrice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.267
AS - Asia 3.765
EU - Europa 3.308
SA - Sud America 658
AF - Africa 127
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 19.136
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.115
SG - Singapore 1.526
RU - Federazione Russa 796
VN - Vietnam 711
IT - Italia 579
HK - Hong Kong 566
BR - Brasile 485
IE - Irlanda 425
CN - Cina 413
DE - Germania 274
FR - Francia 270
SE - Svezia 263
UA - Ucraina 220
GB - Regno Unito 149
IN - India 134
BD - Bangladesh 100
FI - Finlandia 90
AR - Argentina 61
CA - Canada 59
MX - Messico 57
NL - Olanda 49
ES - Italia 44
PL - Polonia 44
IQ - Iraq 41
JP - Giappone 41
ZA - Sudafrica 34
CI - Costa d'Avorio 30
TR - Turchia 29
VE - Venezuela 26
AT - Austria 25
CO - Colombia 23
PK - Pakistan 23
BE - Belgio 21
UZ - Uzbekistan 21
EC - Ecuador 20
MA - Marocco 20
PH - Filippine 19
SA - Arabia Saudita 19
PY - Paraguay 15
TH - Thailandia 13
ID - Indonesia 11
LT - Lituania 11
AE - Emirati Arabi Uniti 10
DZ - Algeria 10
CL - Cile 9
JO - Giordania 9
KR - Corea 9
AU - Australia 8
TN - Tunisia 8
TW - Taiwan 8
AZ - Azerbaigian 7
EG - Egitto 7
IL - Israele 7
MY - Malesia 7
BO - Bolivia 6
HN - Honduras 6
JM - Giamaica 6
KE - Kenya 6
LB - Libano 6
OM - Oman 5
PS - Palestinian Territory 5
RS - Serbia 5
UY - Uruguay 5
AL - Albania 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
KZ - Kazakistan 4
NG - Nigeria 4
NP - Nepal 4
PE - Perù 4
RO - Romania 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BG - Bulgaria 3
CH - Svizzera 3
GR - Grecia 3
HU - Ungheria 3
PA - Panama 3
PR - Porto Rico 3
BH - Bahrain 2
CR - Costa Rica 2
DM - Dominica 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GD - Grenada 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
HR - Croazia 2
KG - Kirghizistan 2
LY - Libia 2
MD - Moldavia 2
MN - Mongolia 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SR - Suriname 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
Totale 19.117
Salva come PNG Salva come JPEG
Città #
Des Moines 1.774
Ashburn 1.402
Singapore 1.118
Chandler 1.018
San Jose 609
Hong Kong 554
Fairfield 535
Dallas 501
Jacksonville 456
Dublin 423
Houston 337
Boardman 278
Wilmington 248
Woodbridge 248
Ho Chi Minh City 234
Seattle 221
Cambridge 216
The Dalles 179
Hanoi 173
Lawrence 163
Princeton 163
Lauterbourg 157
San Mateo 142
New York 139
Council Bluffs 138
Los Angeles 137
Ann Arbor 123
Moscow 111
Beijing 101
Redmond 87
Milan 79
San Diego 65
Helsinki 62
Washington 61
Santa Clara 54
Munich 52
Pune 51
Chicago 50
Orem 46
São Paulo 46
Da Nang 38
London 36
Hefei 34
Tokyo 34
Warsaw 32
San Francisco 31
Abidjan 30
Frankfurt am Main 29
Nuremberg 28
Montreal 26
Stockholm 26
Turku 26
Chennai 25
Columbus 25
Phoenix 24
Rome 24
Miano 23
Haiphong 21
Manchester 21
Mexico City 21
Ancona 20
Centro 20
Salt Lake City 20
Amsterdam 19
Atlanta 19
Buffalo 19
Tashkent 19
Denver 17
Baghdad 16
Boston 16
Brussels 16
Brooklyn 15
Guangzhou 15
Falls Church 13
Florence 13
Kilburn 13
Mumbai 13
Norwalk 13
Shanghai 13
Toronto 13
Cedar Knolls 12
Johannesburg 12
Hải Dương 11
Miami 11
Riyadh 11
Brasília 10
Charlotte 10
Madrid 10
Shenzhen 10
St Petersburg 10
Can Tho 9
New Delhi 9
Querétaro 9
Rio de Janeiro 9
Tampa 9
Wuhan 9
Amman 8
Ankara 8
Belo Horizonte 8
Campinas 8
Totale 13.620
Salva come PNG Salva come JPEG
Nome #
Contraindications to immunotherapy: A global approach 370
Anaphylaxis in Elderly Patients-Data From the European Anaphylaxis Registry 280
The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper 258
Idiopathic anaphylaxis 256
Insights from comparison of serum IgG4 between T2-eosinophilic asthma and eosinophilic granulomatosis with polyangiitis/idiopathic hypereosinophilic syndrome 252
Anaphylaxis 191
Diagnosing, managing and preventing anaphylaxis: Systematic review 184
ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics 175
Rhinopharyngoscopy, computed tomography and magnetic resonance imaging 172
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 166
Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic 161
Anaphylaxis to baobab fruit: The paradox of “natural healthy food” 160
Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old 158
Clinical aspects of hymenoptera venom allergy and venom immunotherapy 156
Development of a model care pathway for the management of Hymenoptera venom allergy: Evidence-based key interventions and indicators 153
EAACI Molecular Allergology User's Guide 152
Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma 150
Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy) 145
EAACI guidelines: Anaphylaxis (2021 update) 144
Fatal anaphylaxis in Italy: Analysis of cause-of-death national data, 2004-2016 143
Diagnosis of Immediate-Type ß-Lactam Allergy In Vitro by Flow-Cytometric Basophil Activation Test and Sulfi doleukotriene Production: a Multicenter Study. 142
Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice? 142
Anaphylaxis in children and adolescents: The European Anaphylaxis Registry 141
Allergen immunotherapy for insect venom allergy: protocol for a systematic review 139
European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? 139
In vivo diagnosis of allergic diseases - allergen provocation tests 137
Advances in Hymenoptera venom immunotherapy 137
Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients 135
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry 134
Why are allergens not detected in the bronchoalveolar lavage fluid of patients undergoing fiberoptic bronchoscopy? Possible explanations 134
Epidemiology of hymenoptera allergy 134
Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes 134
The role of component-resolved diagnosis in Hymenoptera venom allergy 133
Is diet partly responsible for differences in COVID-19 death rates between and within countries? 133
Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis 132
Large local reactions to Hymenoptera stings: outcome of re-stings in real-life 132
Risk Factors and Characteristics of Biphasic Anaphylaxis 131
CAP-Inhibition, Molecular Diagnostics, and Total IgE in the Evaluation of Polistes and Vespula Double Sensitization 129
A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study 129
Shedding Light on the Venom Proteomes of the Allergy-Relevant Hymenoptera Polistes dominula (European Paper Wasp) and Vespula spp. (Yellow Jacket) 128
Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment 128
Efficacy of an air‐cleaning device equipped with a high efficiency particulate air filter in house dust mite respiratory allergy 127
Diagnosis of Hymenoptera venom allergy 127
Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European Anaphylaxis Registry 126
Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice 126
Safety of a 2-day ultrarush immunotherapy in vespid allergic patients: Focus on elevated serum tryptase 125
Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy 125
Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy 125
World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis 124
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy 124
Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry 124
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies 122
Editorial: Anaphylaxis – A Distinct Immunological Syndrome, but How Much Do We Really Understand? 122
Oxytocin: a likely underestimated risk for anaphylactic reactions in delivering women sensitized to latex 121
Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients 119
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper 118
Hymenoptera Venom Allergy: Management of children and adults in clinical practice 118
World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings 118
Bonifazi F. Epidemiology of Hymenoptera sting anaphylaxis 118
Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper 117
Allergy to stings and bites from rare or locally important arthropods: Worldwide distribution, available diagnostics and treatment 116
Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation? 116
EAACI anaphylaxis guidelines: Systematic review protocol 115
Common Variable Immunodeficiency in Elderly Patients: A Long-Term Clinical Experience 115
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 114
Immunotherapy for hymenoptera venom allergy: too expensive for European health care? 114
Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper 113
Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? 112
2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis 112
COVID-19 lockdown, personal protective equipment, hyper-hygiene and allergy 112
Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase 111
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients 110
Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis 109
High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience 109
World Allergy Organization anaphylaxis guidelines: Summary 109
Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations 109
International consensus on (ICON) anaphylaxis 109
Intraoperative anaphylaxis: verba volant, scripta manent! 109
Hymenoptera Venom Immunotherapy: How to Safely Switch to the Same Venom From a Different Manufacturer 108
High long-term efficacy of venom immunotherapy after discontinuation 108
Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria) 107
Lysozyme, a new allergen in donkey's milk 106
Congruence between international guidelines and mite specific immunotherapy prescribing practices 106
A narrative review on asthma and pest sensitization (cockroach, mouse and rat allergens): a social issue besides the medical problem. 105
The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts 105
The dilemma of the negative skin test reactors with a history of venom anaphylaxis: will this always be the case? 105
Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper 104
Adherence to the rhinitis management plan of allergic rhinitis 104
Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe 103
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy 103
Efficacy of mepolizumab in patients with concomitant severe eosinophilic asthma and severe chronic urticaria: an example of personalized medicine? 103
A case of fatal biphasic anaphylaxis secondary to multiple stings: adrenalin and/or a longer observation time could have saved the patient? 102
The natural history and epidemiology of insect venom allergy: clinical implications 102
Insect sting anoxic encephalopathy after stopping venom immunotherapy. 102
Platelet-activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy? 102
Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. 99
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity 99
Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy 99
Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry 98
Recommendations for the Use of Tryptase in the Diagnosis of Anaphylaxis and Clonal Mastcell Disorders 98
Totale 13.257
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.237
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.237
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.200 61 235 18 35 21 69 46 94 106 75 132 308
2022/20234.055 228 212 169 261 177 1.998 1 167 588 23 166 65
2023/20241.392 268 39 119 139 223 271 23 46 7 53 19 185
2024/20252.735 100 232 100 74 63 174 207 94 809 210 257 415
2025/20266.946 342 397 414 512 711 545 1.416 768 674 598 272 297
2026/2027357 357 0 0 0 0 0 0 0 0 0 0 0
Totale 19.441